TGTX Q2 2023 Earnings — TG Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

TGTXTG Therapeutics, Inc.

$5B

Q2 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$16M+2606.1% YoY

Gross Profit

$14M88.1% margin

Operating Income

-$45M-277.9% margin

Net Income

-$48M-296.2% margin

EPS (Diluted)

$-0.34

QoQ Revenue Growth

+106.0%

Cash Flow

Operating Cash Flow

-$42M

Free Cash Flow

-$42M

Stock-Based Comp.

$13M

Balance Sheet

Total Assets

$221M

Total Liabilities

$180M

Stockholders' Equity

$40M

Cash & Equivalents

$97M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$16M	$594,000	+2606.1%
Gross Profit	$14M	$571,000	+2380.4%
Operating Income	-$45M	-$39M	-14.7%
Net Income	-$48M	-$41M	-17.5%

Revenue Segments

Product revenue, net

$16M100%

License revenue

$38,0000%